Evidence map›Paper›PMID 34123276›Full record

ArticleChemical science2020

Tri-functional platform for construction of modular antibody fragments for

Raymond F Gamache, Kirstin A Zettlitz, Wen-Ting K Tsai, Jeffrey Collins, Anna M Wu, Jennifer M Murphy

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Site-Specific and Residualizing Linker forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Raymond F GamacheDepartment of Chemistry and Biochemistry, University of California Los Angeles CA 90095 USA.
Kirstin A ZettlitzDepartment of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA jmmurphy@mednet.ucla.edu.ORCID https://orcid.org/0000-0003-4870-6603
Wen-Ting K TsaiDepartment of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA jmmurphy@mednet.ucla.edu.
Jeffrey CollinsDepartment of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA jmmurphy@mednet.ucla.edu.
Anna M WuDepartment of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA jmmurphy@mednet.ucla.edu.
Jennifer M MurphyDepartment of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles CA 90095 USA jmmurphy@mednet.ucla.edu.ORCID https://orcid.org/0000-0002-8492-4918
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Multifunctional immunoPET tracers for pancreatic and prostate cancerR01CA174294 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E, WU, ANNA M · 2013 to 2020
$3.3M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA174294
6 · The paper itself

Abstract

Positron emission tomography (PET) molecular imaging is a powerful tool for interrogating physiological and biochemical processes to understand the biology of disease and advance therapeutic developments. Near-infrared fluorescence (NIRF) optical imaging has become increasingly popular for intraoperative staging to enable cellular resolution imaging of tumor margins during surgical resection. In addition, engineered antibody fragments have emerged as promising molecular imaging agents given their exquisite target selectivity, rapid systemic clearance and site-selective chemical modification. We report a tri-functional platform for construction of a modular antibody fragment that can rapidly be labeled with radionuclides or fluorophores for PET or NIRF molecular imaging of prostate stem cell antigen (PSCA).

Identifiers

PMID34123276
PMCPMC8148382
OpenAlexW2999711324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.